**Topic Brief: Accelerated Partial Breast Irradiation for Breast Cancer**

**Date:** 12/31/2020  
**Nomination Number:** 0932

**Purpose:** This document summarizes the information addressing a nomination submitted on July 17, 2020 through the Effective Health Care Website. This information was used to inform the Evidence-based Practice Center (EPC) Program decisions about whether to produce an evidence report on the topic, and if so, what type of evidence report would be most suitable.

**Issue:** There is a high incidence of breast cancer diagnosis among women, and radiation therapy is an integral part of breast cancer treatment. Providing current evidence on radiation therapy for breast cancer is an important public health initiative. The current guidelines on accelerated partial breast irradiation (PBI) for breast cancer from the American Society for Radiation Oncology (ASTRO) were published in 2016. A new systematic review of current evidence would address uncertainties in the delivery and patient selection for different types of breast irradiation; and facilitate an update to the existing guideline to best inform practice.

**Recommendation**
- X Systematic review
- □ Technical brief
- □ Evidence map
- □ Rapid review
- □ Rapid response
- □ Expanded topic brief

**Key Findings**
- From a sample of 200 out of 878 studies published between 2017 and 2020, we found sufficient evidence for a new systematic review addressing all but one of five Key Questions (KQs).

**Background**
In 2017, female breast cancer was the form of cancer with the highest incidence of new cases and the second highest incidence of death in the United States.1 The most common treatment for breast cancer is breast-conserving surgery with adjuvant radiation therapy.2 The goal of radiation therapy in breast cancer treatment is to eradicate subclinical disease following the surgical removal of tumors.3

Radiation therapy administered in patients with early stage breast cancer reduces tumor recurrence and increases survival.4 According to ASTRO, the recommended dose-fractionation scheme for whole breast irradiation (WBI) is hypofractionated to 4000 cGy in 15 fractions or
4250 cGy in 16 fractions. Variations in technique from standard whole breast radiation therapy aim to reduce treatment time, facilitate convenience, and/or limit radiation exposure to normal tissue. Accelerated PBI is one such technique, and has been shown to accomplish some of these aims. As part of PBI, radiation is delivered to tissue only immediately adjacent to the site of the removed tumor, and is convenient in that it can be completed in five treatment days. Methods of PBI include multicablether brachytherapy, intracavitary balloon brachytherapy, intraoperative radiation therapy, and external beam conformal therapy.

Despite an evidence base with findings that support strong, evidence-based recommendations, contemporary studies of PBI continue to demonstrate significant variation in care. Clinicians face difficult patient presentations where numerous factors related to patient-specific values and expectations, and varied imaging and clinical features that must be considered, all of which appear to make it more difficult to provide care that is consistent with guideline recommendations. A new systematic review would serve to facilitate the development of an update to the current ASTRO 2016 guidelines that would include information that could provide indications for more tailored treatment based on patient characteristics and clinical features.

Scope

1. In adult women with early stage breast cancer, what is the comparative effectiveness of whole breast irradiation (WBI) compared to partial breast irradiation (PBI)? Which clinical-pathologic characteristics are associated with effectiveness for PBI compared to WBI?
2. In adult women with early stage breast cancer receiving PBI, what is the comparative effectiveness of PBI techniques (e.g., multicablether interstitial brachytherapy, single-entry catheter brachytherapy [including devices such as MammoSite, Contura, and SAVI], 3-dimensional conformal external beam radiation therapy, intensity modulated radiation therapy, and proton radiation therapy, intra-operative radiotherapy) on ipsilateral breast cancer outcomes, harms, and quality of life?
3. In adult women with early stage breast cancer, what is the comparative effectiveness of different dose-fractionation schemes, target volumes, motion management, treatment techniques and optimal planning parameters for accelerated PBI compared to WBI on breast cancer outcomes, harms, and quality of life?
4. In adult women with early stage breast cancer, what is the comparative effectiveness of preoperative compared to postoperative imaging assessment for patients who meet clinical-pathologic criteria for treatment with PBI?
5. In adult women with early stage breast cancer, what is the comparative effectiveness in terms of cosmesis and treatment toxicities between PBI and WBI?

Table 1. Questions and PICO (population, intervention, comparator, outcome)

<table>
<thead>
<tr>
<th>Questions</th>
<th>Population</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. PBI vs. WBI</td>
<td>Adult women with early stage breast cancer (invasive or non-invasive carcinoma less than or equal to 3 cm and NO/1).</td>
</tr>
<tr>
<td>2. PBI techniques</td>
<td>Adult women with early stage breast cancer (invasive or non-invasive carcinoma less than or equal to 3 cm and NO/1) receiving PBI.</td>
</tr>
<tr>
<td>3. Dose fractionation schemes, target volumes, etc. in PBI vs. WBI</td>
<td>Adult women with early stage breast cancer (invasive or non-invasive carcinoma less than or equal to 3 cm and NO/1).</td>
</tr>
<tr>
<td><strong>Interventions</strong></td>
<td>PBI</td>
</tr>
<tr>
<td>------------------</td>
<td>-----</td>
</tr>
<tr>
<td><strong>Comparators</strong></td>
<td>WBI</td>
</tr>
<tr>
<td><strong>Outcomes</strong></td>
<td>breast cancer recurrence, survival, cancer-free survival</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Questions</strong></th>
<th>4. Pre- vs. post-operative imaging assessment</th>
<th>5. Cosmesis and treatment toxicity in PBI vs. WBI</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Population</strong></td>
<td>Adult women with early stage breast cancer (invasive or non-invasive carcinoma less than or equal to 3 cm and NO/1) who meet clinical-pathologic criteria for treatment with PBI.</td>
<td>Adult women with early stage breast cancer (invasive or non-invasive carcinoma less than or equal to 3 cm and NO/1)</td>
</tr>
<tr>
<td><strong>Interventions</strong></td>
<td>Post-operative imaging assessment for PBI</td>
<td>PBI</td>
</tr>
<tr>
<td><strong>Comparators</strong></td>
<td>Pre-operative imaging assessment for PBI</td>
<td>WBI</td>
</tr>
<tr>
<td><strong>Outcomes</strong></td>
<td>Cavity visualization score, harms</td>
<td>Cosmesis, treatment toxicities, other short- and long-term harms (e.g., Radiation Therapy Oncology Group scores and Late Effects Normal Tissue Task Force -- Subjective, Objective, Management, Analytic scales)</td>
</tr>
</tbody>
</table>

Abbreviations: IORT= intra-operative radiotherapy, PBI= partial breast irradiation, WBI= whole breast irradiation.

**Assessment Methods**
See Appendix A.

**Summary of Literature Findings**
To address clinical uncertainties and inform an update to the existing ASTRO 2016 guideline, we sampled (200 out of 878 studies) from studies published between 2017 and 2020. In that sample, we found studies relevant to all but KQ4.
For KQ1, we found three randomized control trials (RCTs)\textsuperscript{9-11} and two observational studies\textsuperscript{12, 13} comparing PBI to WBI that measured the targeted outcomes, local tumor control and survival. Additionally, we found three RCTs comparing PBI and WBI that reported quality of life outcomes.\textsuperscript{14-16} While quality of life was not an outcome included for KQ1, it might ultimately be of interest.

For KQ2, we found one observational study comparing interstitial brachytherapy, balloon-based brachytherapy, and 3-D conformal radiation therapy on tumor recurrence.\textsuperscript{17}

For KQ3, we found two RCTs; one that compared two different PBI fractionation schemes using two different techniques to WBI,\textsuperscript{18} and one that compared PBI fractionation schemes, but without a comparison to WBI.\textsuperscript{19}

We did not find any studies addressing KQ4.

For KQ5, we found four RCTs\textsuperscript{20-23} and one clinical trial\textsuperscript{24} comparing PBI with WBI on cosmesis and/or toxicity. Though not directly applicable to the scope of this nomination we found 10 single arm studies measuring cosmesis and/or toxicity in PBI, but without a comparison to WBI.\textsuperscript{25-34}

Table 2. Literature identified for each KQ

<table>
<thead>
<tr>
<th>Question</th>
<th>Systematic reviews (11/2017-11/2020)</th>
<th>Primary studies (11/2017-11/2020)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Question 1: PBI vs. WBI</td>
<td>Total: 0</td>
<td>Total: 8</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• RCT: 6</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Observational: 2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Clinicaltrials.gov: 0</td>
</tr>
<tr>
<td>Question 2: PBI techniques</td>
<td>Total: 0</td>
<td>Total: 1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• RCT: 0</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Observational: 1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Clinicaltrials.gov: 0</td>
</tr>
<tr>
<td>Question 3: Dose fractionation schemes, target volumes, etc. in PBI vs. WBI</td>
<td>Total: 0</td>
<td>Total: 2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• RCT: 2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Observational: 0</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Clinicaltrials.gov: 0</td>
</tr>
<tr>
<td>Question 4: PBI imaging assessment</td>
<td>Total: 0</td>
<td>Total: 0</td>
</tr>
<tr>
<td>Question 5: cosmesis and toxicity in PBI vs. WBI</td>
<td>Total: 0</td>
<td>Total: 4</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• RCT: 4</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Observational: 0</td>
</tr>
</tbody>
</table>

Abbreviations: KQ=Key question; PBI=partial breast irradiation; RCT=randomized controlled trial; WBI=whole breast irradiation.
See Appendix B for detailed assessments of all EPC selection criteria.

**Summary of Selection Criteria Assessment**

This nomination meets all selection criteria. We found sufficient primary evidence for a new systematic review for all but one of five KQs. A new systematic review would inform clinical uncertainty in treatment and the update of the existing 2016 ASTRO guidelines on PBI.

Please see Appendix B for detailed assessments of individual EPC Program selection criteria.

**References**


Author
Emily Gean

Conflict of Interest: None of the investigators have any affiliations or financial involvement that conflicts with the material presented in this report.

Acknowledgements
Christine Chang
Robin Paynter
Kelly Vander Ley
Charli Armstrong

This report was developed by the Scientific Resource Center under contract to the Agency for Healthcare Research and Quality (AHRQ), Rockville, MD (Contract No. HHSA 290-2017-0003C). The findings and conclusions in this document are those of the author(s) who are responsible for its contents; the findings and conclusions do not necessarily represent the views of AHRQ. No statement in this article should be construed as an official position of the Agency for Healthcare Research and Quality or of the U.S. Department of Health and Human Services.

Persons using assistive technology may not be able to fully access information in this report. For assistance contact EPC@ahrq.hhs.gov.
Appendix A: Methods

We assessed nomination for priority for a systematic review or other AHRQ Effective Health Care report with a hierarchical process using established selection criteria. Assessment of each criteria determined the need to evaluate the next one. See Appendix B for detailed description of the criteria.

Appropriateness and Importance
We assessed the nomination for appropriateness and importance.

Desirability of New Review/Absence of Duplication
We searched for high-quality, completed or in-process evidence reviews published in the last three years November 24, 2017 - November 24, 2020 on the questions of the nomination from these sources:

- AHRQ: Evidence reports and technology assessments
  - EHC Program [https://effectivehealthcare.ahrq.gov/](https://effectivehealthcare.ahrq.gov/)
  - AHRQ Technology Assessment Program [https://www.ahrq.gov/research/findings/ta/index.html](https://www.ahrq.gov/research/findings/ta/index.html)

- US Department of Veterans Affairs Products publications
  - VA/Department of Defense Evidence-Based Clinical Practice Guideline Program [https://www.healthquality.va.gov/](https://www.healthquality.va.gov/)

- Cochrane Systematic Reviews [https://www.cochranelibrary.com/](https://www.cochranelibrary.com/)
- PROSPERO Database (international prospective register of systematic reviews and protocols) [http://www.crd.york.ac.uk/prospero/](http://www.crd.york.ac.uk/prospero/)

Impact of a New Evidence Review
The impact of a new evidence review was qualitatively assessed by analyzing the current standard of care, the existence of potential knowledge gaps, and practice variation. We considered whether it was possible for this review to influence the current state of practice through various dissemination pathways (practice recommendation, clinical guidelines, etc.).

Feasibility of New Evidence Review
We conducted a limited literature search in PubMed from the last three years since the current PBI guideline was published, November 24, 2017- November 24, 2020, on all key questions. Because a large number of articles were identified, we reviewed a random sample of 200 titles and abstracts for inclusion. We classified identified studies by question and study design, to assess the size and scope of a potential evidence review. We then calculated the projected total number of included studies based on the proportion of studies included from the random sample.

Search strategy
**Ovid MEDLINE ALL 1946 to November 24, 2020**
ClinicalTrials.gov [expert search mode]
Date searched: November 25, 2020
( early OR EXPAND[Concept] "stage 0" OR EXPAND[Concept] "stage 1" OR EXPAND[Concept] "stage 1a" OR EXPAND[Concept] "stage 1b" OR EXPAND[Concept] "stage 2" OR EXPAND[Concept] "stage 2a" OR EXPAND[Concept] "stage 2b" OR EXPAND[Concept] "stage I" OR EXPAND[Concept] "stage Ia" OR EXPAND[Concept] "stage Ib" OR EXPAND[Concept] "stage II" OR EXPAND[Concept] "stage IIa" OR EXPAND[Concept] "stage IIb" OR EXPAND[Concept] "stage zero" OR EXPAND[Concept] "stage one" OR EXPAND[Concept] "stage two" OR EXPAND[Concept] "Accelerated Partial Breast" OR APBI OR VAPBI OR brachytherap* OR irradiation OR radiotherap* OR radiation OR re-irradiation OR HWBI OR IORT OR WBI ) AND ( AREA[ConditionSearch] ( breast AND ( cancer OR carcinoma ) ) OR AREA[TitleSearch] ( breast AND cancer or carcinoma ) ) AND AREA[OverallStatus] EXPAND[Term] COVER[FullMatch] ( "Active, not recruiting" OR "Completed" ) AND AREA[InterventionSearch] ( EXPAND[Concept] "Accelerated Partial Breast" OR APBI OR VAPBI OR brachytherap OR irradiation OR radiotherap OR radiation OR re-irradiation OR HWBI OR IORT OR WBI ) AND AREA[Gender] EXPAND[Term] COVER[FullMatch] NOT "Male" AND AREA[StdAge] EXPAND[Term] COVER[FullMatch] ( "Adult" OR "Older Adult" ) AND AREA[StudyFirstPostDate] EXPAND[Term] RANGE[01/01/2017, 11/25/2020]

(72) TRIAL RESULTS
clinicaltrials.gov link

Value
We assessed the nomination for value. We considered whether or not the clinical, consumer, or policymaking context had the potential to respond with evidence-based change; and if a partner organization would use this evidence review to influence practice.
### Appendix B. Selection Criteria Assessment

<table>
<thead>
<tr>
<th>Selection Criteria</th>
<th>Assessment</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Appropriate</td>
<td></td>
</tr>
<tr>
<td>1a. Does the nomination represent a health care drug, intervention, device, technology, or health care system/setting available (or soon to be available) in the United States?</td>
<td>Yes</td>
</tr>
<tr>
<td>1b. Is the nomination a request for an evidence report?</td>
<td>Yes</td>
</tr>
<tr>
<td>1c. Is the focus on effectiveness or comparative effectiveness?</td>
<td>Yes</td>
</tr>
<tr>
<td>1d. Is the nomination focus supported by a logic model or biologic plausibility?</td>
<td>Yes</td>
</tr>
<tr>
<td>1c. Is the focus on effectiveness or comparative effectiveness?</td>
<td>Yes</td>
</tr>
<tr>
<td>2. Importance</td>
<td></td>
</tr>
<tr>
<td>2a. Represents a significant disease burden; large proportion of the population</td>
<td></td>
</tr>
<tr>
<td>As measured in 2017, female breast cancer was the cancer type with the highest incidence of new cases (125 in 100,000 people; 250,000 new cases) and with the second highest incidence of death in the U.S. (19.9 per 100,000 women; 42,000 deaths).</td>
<td>Yes</td>
</tr>
<tr>
<td>2b. Is of high public interest; affects health care decision making, outcomes, or costs for a large proportion of the United States population or for a vulnerable population</td>
<td>Yes. As measured in 2017, female breast cancer was the cancer type with the highest incidence of new cases (125 in 100,000 people; 250,000 new cases) and with the second highest incidence of death in the U.S. (19.9 per 100,000 women; 42,000 deaths).</td>
</tr>
<tr>
<td>2c. Incorporates issues around both clinical benefits and potential clinical harms</td>
<td>Yes</td>
</tr>
<tr>
<td>2d. Represents high costs due to common use, high unit costs, or high associated costs to consumers, to patients, to health care systems, or to payers</td>
<td>Yes. As measured in 2016, costs in the year after diagnosis for all stages of breast cancer ranged from $60,637 to $134,682, and, in the 24 months after diagnosis, $71,909-$182,655.</td>
</tr>
<tr>
<td>3. Desirability of a New Evidence Review/Absence of Duplication</td>
<td></td>
</tr>
<tr>
<td>3. A recent high-quality systematic review or other evidence review is not available on this topic</td>
<td>Yes. We did not find any existing systematic reviews that would be appropriate for the time period since the current guideline was published.</td>
</tr>
<tr>
<td>4. Impact of a New Evidence Review</td>
<td></td>
</tr>
<tr>
<td>4a. Is the standard of care unclear (guidelines not available or guidelines inconsistent, indicating an information gap that may be addressed by a new evidence review)?</td>
<td>Yes. Despite an evidence base with findings that support strong, evidence-based recommendations, contemporary studies continue to demonstrate significant variation in care. Clinicians face difficult patient presentations where numerous factors related to patient-specific values and expectations, and varied imaging and clinical features that must be considered, all of which appear to make it more difficult to provide care that is consistent with guideline recommendations.</td>
</tr>
<tr>
<td>4b. Is there practice variation (guideline inconsistent with current practice, indicating a potential implementation gap and not best addressed by a new evidence review)?</td>
<td>Yes. Clinicians face difficult patient presentations where numerous factors related to patient-specific values and expectations, and varied imaging and clinical features that must be considered, all of which appear to make it more difficult to provide care that is consistent with guideline recommendations.</td>
</tr>
<tr>
<td>5. Primary Research</td>
<td></td>
</tr>
</tbody>
</table>
5. Effectively utilizes existing research and knowledge by considering:
   - Adequacy (type and volume) of research for conducting a systematic review
   - Newly available evidence (particularly for updates or new technologies)
   We found a total of 15 primary studies addressing four of five KQs. We did not find any studies addressing KQ4.
   We took a sample (200 studies) from a total of 878 studies published between 2017 and 2020. We estimate that a new systematic review would be medium in size (66 studies).

6. **Value**

<table>
<thead>
<tr>
<th>6a. The proposed topic exists within a clinical, consumer, or policy-making context that is amenable to evidence-based change</th>
<th>Yes, ASTRO plans to use a new systematic review to update the existing guidelines.</th>
</tr>
</thead>
<tbody>
<tr>
<td>6b. Identified partner who will use the systematic review to influence practice (such as a guideline or recommendation)</td>
<td>Yes, ASTRO, the nominator, plans to use a new systematic review to update their existing guidelines.</td>
</tr>
</tbody>
</table>

Abbreviations: AHRQ=Agency for Healthcare Research and Quality; ASTRO=American Society of Radiation Oncology; KQ=key question.
Appendix C. Topic Nomination
A topic nomination was submitted on the EHC website:
Submitted on Friday, July 17, 2020 - 14:38

==Topic Suggestion==
1. What is the decision or change you are facing or struggling with where a summary of the
evidence would be helpful?
1:8 women will be diagnosed with breast cancer in their lifetime. Therefore, providing the most
recent evidence for treatment of this prevalent disease is an important public health initiative.
Additionally, radiation therapy is integral to the treatment of breast cancer. ASTRO has
previously published consensus statements on accelerated partial breast irradiation (APBI) in
2009 and 2016. In accordance with the National Academy of Medicine (formerly Institute of
Medicine) standards for the development of high quality, evidence-based clinical practice
guidelines, ASTRO intends to use the evidence report developed by AHRQ as the basis to
replace the previous documents to ensure that current guidance provided to clinicians is accurate,
and reflects current evidence. The following key questions will be addressed:
KQ 1: In patients with early stage breast cancer, what are the appropriate indications and criteria
of patient selection for APBI, and how does this differ from whole breast irradiation?
KQ 2: In patients with early stage breast cancer, what are the differences of ipsilateral breast
tumor control rates between whole breast and the different APBI techniques?
KQ 3: In patients with early stage breast cancer, what are the appropriate dose-fractionation
schemes, target volumes, and optimal planning parameters for APBI.
KQ 4: In patients with early stage breast cancer receiving APBI, how do the different treatment
planning techniques (3-D, IMRT, HDR cavity brachytherapy, HDR interstitial brachytherapy)
impact on treatment toxicities and quality of life?
KQ 5: In patients with early stage breast cancer, what is the optimal imaging assessment for
patients considering APBI?
KQ6: In patients with early stage breast cancer, what are the differences in cosmesis and
treatment toxicities between APBI and whole breast irradiation?
The population of patients that will be assisted by this guideline are those with early stage breast
cancer. Early stage breast cancer is defined as invasive or non-invasive carcinoma less than or
equal to 3 cm and N0/1. The interventions that will be evaluated in this guideline are whole
breast versus APBI. The comparison groups that will be utilized in this guideline will include
patients who receive whole breast irradiation versus APBI. The outcomes that will be examined
in this guideline include ipsilateral breast local control, short- and long-term toxicity.

2. Why are you struggling with this issue?
Because of the prevalence and early detection of breast cancer, there are many studies on the
optional treatment options for women. It is critical that ASTRO, the leading radiation therapy
society within the US, provide the most accurate and up-to-date guidelines regarding this
disease. It is critical that these patients are offered the most effective, safe, evidence-based, and
patient-centered recommendations to optimize the likelihood of benefit and minimize the
potential for treatment-related toxicity, whether physical, financial, psychological, or otherwise.
Despite an evidence base with findings that support strong, evidence-based recommendations,
contemporary studies continue to demonstrate significant variation in care. Clinicians face
difficult patient presentations where numerous factors related to patient-specific values and
expectations, and varied imaging and clinical features that must be considered, all of which
appear to make it more difficult to provide care that is consistent with guideline
recommendations. Given the multifactorial issues that face the patient and their healthcare
providers, in realizing the benefits of treatment while reducing risk and adhering to evidence-based standards, it is critically important to educate both groups to empower good medical decision-making in the face of a highly curative disease.

3. What do you want to see changed? How will you know that your issue is improving or has been addressed?
One goal of publishing this clinical practice guideline is to achieve a significantly higher rate of radiation treatment courses that adhere to the evidence-based standards that are recommended in ASTRO clinical practice guidelines on the treatment of early stage breast cancer. There are several groups that regularly measure patterns of care and publish on adherence with ASTRO guidelines. ASTRO will collaborate and support patterns of care studies to measure and compare rates of concordance with evidence-based recommendations for the treatment of patients with early stage breast cancer to evaluate whether this issue is improving or has been addressed.

4. When do you need the evidence report? Mon, 08/01/2022

5. What will you do with the evidence report?
ASTRO intends to use the evidence report developed by AHRQ as the basis for a comprehensive evidence-based, clinical practice guideline on accelerated partial breast irradiation. An AHRQ report, with a literature search, data extraction, and analysis according to the highest standards of systematic reviews, would significantly aid in the completion of a guideline to provide timely, current, evidence-based recommendations to clinicians in an area of great clinical importance. ASTRO guidelines are scientifically and methodologically rigorous and are published in high impact journals. They are also widely read and cited by cancer care providers, as demonstrated by citation frequency and quantitative measurement of downloads from the journal website. Once an AHRQ report is available, the ASTRO Guidelines Subcommittee will convene a panel of disease-site experts and general cancer care practitioners from academic, community, and government-run practice settings, including a patient representative and physician-in-training representative, to complete this important guideline. ASTRO staff with expertise in clinical practice guideline development will support this process.

---Supporting Document---
Upload Document:
https://effectivehealthcare.ahrq.gov/sites/default/files/webform/docs/APBI%202017%20Guideline.pdf
Title or short description: Evidence review request on accelerated partial breast irradiation (APBI)
Comments or notes about this file: ASTRO has worked with AHRQ on previous reviews in support of clinical practice guidelines and has an understanding regarding the timelines involved with these processes. This guideline topic was selected based on a high level of confidence that an anticipated timeline of 2 years for completion is appropriate, and our disease-site experts believe there is adequate flexibility based on the recent literature and clinical trial publications, at this timeline will be appropriate for this guideline project.

---(Optional) About You---
What is your role or perspective? Radiation therapy professional society
If you are you making a suggestion on behalf of an organization, please state the name of the organization: American Society of Radiation Oncology
May we contact you if we have questions about your nomination? Yes
First and Last Name: Lisa Bradfield
Title: Senior Manager of Guidelines and QI
Email Address: Lisa.bradfield@astro.org

The results of this submission may be viewed at:
https://effectivehealthcare.ahrq.gov/node/16119/submission/19157